Last reviewed · How we verify
JX11502MA
At a glance
| Generic name | JX11502MA |
|---|---|
| Sponsor | Zhejiang Jingxin Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia. (PHASE1, PHASE2)
- A Safety，Tolerability and Pharmacokinetics Clinical Trial of JX11502MA Capsule (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JX11502MA CI brief — competitive landscape report
- JX11502MA updates RSS · CI watch RSS
- Zhejiang Jingxin Pharmaceutical Co., Ltd. portfolio CI